Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)

NCT06239220 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06239220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06239220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
February 16, 2024
Completion date
March 31, 2027
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck squamous cell carcinoma, metastatic head and neck cancer, metastatic head-and-neck squamous-cell carcinoma, recurrent head and neck cancer, recurrent head and neck squamous cell carcinoma